Trial Profile
Phase I/II study of carboplatin plus nab-paclitaxel plus bevacizumab administered to advanced non-squamous non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Bevacizumab; Carboplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 20 Mar 2014 New trial record